1. North of England Hypertension Guideline Development Group. Essential hypertension: managing adults in primary care. 2004. (University of Newcastle on Tyne, Centre for Health Services Research report No 111.) www.nice.org.uk/pdf/CG018fullguideline.pdf (accessed 21 Mar 2005).
  2. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure. Hypertension 2003;42:1206-52.
  3. Williams B, Poulter NR, Brown MJ, Davis M, McInnes GT, Potter JF, et al. Guidelines for management of hypertension: report of the fourth working party of the British Hypertension Society. J Hum Hypertens 2004;18:139-85.
  4. European Society of Hypertension/European Society of Cardiology Guidelines Committee. 2003 European Society of Hypertension/European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 2003;21:1011-53.
  5. Dahlof B, Sever PS, Poulter NR, Wedel H, Beevers GD, Caulfield M, et al. Prevention of cardiovascular events with an antihyepretensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian cardiac outcomes trial-blood pressure lowering arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005;366:895-906.
  6. Poulter NR, Wedel H, Dahlof B, Sever PS, Beevers GD, Caulfield M, et al. Role of blood pressure and other variables in the differential cardiovascular event rates noted in the Anglo-Scandinavian cardiac outcomes trial-blood pressure lowering arm (ASCOT-BPLA). Lancet 2005;366:907-13.
  7. Verma S, Strauss M. Angiotensin receptor blockers and myocardial infarction.
    BMJ 2004;329:1248-9.
  8. McDonald MA, Simpson SH, Ezekowitz JA, Gyenes G, Tsuyuki RT. Angiotensin receptor blockers and risk of myocardial infarction: systematic review. BMJ 2005; 331:873-6.
  9. McMurray J. Angiotensin receptor blockers and myocardial infarction: analysis of evidence is incomplete and inaccurate. BMJ 2005;330:1269.
  10. Scheen AJ. Renin-angiotensin system inhibition prevents type 2 diabetes mellitus. Part 1. A meta-analysis of randomised clinical trials. Diabetes Metab 2004;30:487-96.
  11. Petrie JR, Kirby M. Too much of a good thing: 2004 guidance from NICE and BHS-IV on hypertension in diabetes. Br J Diab Vasc Dis 2004;4:365-8.
  12. Carlberg B, Samuelsson O, Lindholm LH. Atenolol in hypertension: is it a wise choice? Lancet 2004; 364:1684-9.

Access jobs at BMJ Careers
Whats new online at Student BMJ